Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Peritoneal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Melanoma 1Limited Stage Small Cell Lung Cancer 1Glioblastoma 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 57Nivolumab 50Ipilimumab 31Specimen Handling 23Magnetic Resonance Spectroscopy 19Cyclophosphamide 14Biopsy 11fludarabine 10binimetinib 10Opdualag 10trametinib 9relatlimab 9Radiosurgery 9CTLA-4 Antigen 9dabrafenib 8lifileucel 7fludarabine phosphate 7aldesleukin 7encorafenib 6Interleukin-2 6cemiplimab 5atezolizumab 5Paclitaxel 5Blood Specimen Collection 5X-Rays 4Taxes 4Pemetrexed 4Gemcitabine 4Cisplatin 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Glucose × 90 days × Clear all
NCT06391099 2026-05-26

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

Ohio State University Comprehensive Cancer Center

Phase NA Suspended
60 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡